Doña Inmaculada, Pérez-Sánchez Natalia, Salas María, Barrionuevo Esther, Ruiz-San Francisco Arturo, Hernández Fernández de Rojas Dolores, Martí-Garrido Jaume, Andreu-Ros Inmaculada, López-Salgueiro Ramón, Moreno Esther, Torres María José
Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Civil, Málaga, Spain; Allergy Unit, Hospital Regional Universitario de Málaga, Hospital Civil, Málaga, Spain.
Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Civil, Málaga, Spain; Allergy Unit, Hospital Regional Universitario de Málaga, Hospital Civil, Málaga, Spain.
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2707-2714.e2. doi: 10.1016/j.jaip.2020.04.051. Epub 2020 May 4.
Quinolones are the second most frequent cause of hypersensitivity reactions (HSRs) to antibiotics. A marked increase in the number of patients with HSRs to quinolones has been detected.
To describe the clinical characteristics of patients with HSRs to quinolones and present methods for their diagnosis.
Patients attending the allergy unit due to reactions suggestive of HSRs to quinolones were prospectively evaluated between 2005 and 2018. Diagnosis was achieved using clinical history, skin tests (STs), basophil activation tests (BATs), and drug provocation tests (DPTs) if ST and BAT results were negative.
We included 128 subjects confirmed as having HSRs to quinolones and 42 found to be tolerant. Anaphylaxis was the most frequent entity in immediate HSRs and was most commonly induced by moxifloxacin. Patients were evaluated a median of 150 days (interquartile range, 60-365 days) after the reaction. Of patients who underwent ST and BAT, 40.7% and 70%, respectively, were positive. DPT with a quinolone was performed in 48 cases, giving results depending on the culprit drug: when moxifloxacin was involved, 62.5% of patients gave a positive DPT result to ciprofloxacin, whereas none reacted to levofloxacin. The risk of HSR was 96 times higher in subjects who reported moxifloxacin-induced anaphylaxis and 18 times higher in those reporting immediate reactions compared with clinical entities induced by quinolones other than moxifloxacin and nonimmediate reactions.
The diagnosis of HSR to quinolones is complex. The use of clinical history is essential as a first step. BAT shows higher sensitivity than STs. DPTs can be useful for finding safe alternative quinolones.
喹诺酮类药物是抗生素过敏反应(HSRs)的第二大常见病因。已检测到对喹诺酮类药物过敏反应患者数量显著增加。
描述对喹诺酮类药物过敏反应患者的临床特征,并介绍其诊断方法。
对2005年至2018年间因疑似对喹诺酮类药物过敏反应而就诊于过敏科的患者进行前瞻性评估。如果皮肤试验(STs)和嗜碱性粒细胞活化试验(BATs)结果为阴性,则通过临床病史、皮肤试验、嗜碱性粒细胞活化试验和药物激发试验(DPTs)进行诊断。
我们纳入了128名确诊对喹诺酮类药物过敏反应的受试者和42名耐受者。速发型过敏反应中,过敏性休克是最常见的类型,最常由莫西沙星诱发。反应发生后,患者接受评估的中位时间为150天(四分位间距,60 - 365天)。接受皮肤试验和嗜碱性粒细胞活化试验的患者中,分别有40.7%和70%的结果呈阳性。48例患者进行了喹诺酮类药物激发试验,结果因致病药物而异:当涉及莫西沙星时,62.5%的患者对环丙沙星激发试验呈阳性反应,而对左氧氟沙星无反应。与由莫西沙星以外的喹诺酮类药物诱发的临床症状和非速发型反应相比,报告莫西沙星诱发过敏性休克的受试者发生过敏反应的风险高96倍,报告速发型反应的受试者高18倍。
对喹诺酮类药物过敏反应的诊断较为复杂。临床病史的应用作为第一步至关重要。嗜碱性粒细胞活化试验显示出比皮肤试验更高的敏感性。药物激发试验有助于找到安全的替代喹诺酮类药物。